Stella Priyanka (Senior Scientist) will be presenting the latest data on our first-in-class soloMER drug conjugate, ELN28, at PEGS Boston Summit, May 2025. Her poster, “Characterization of a Bi-Functional soloMER® Drug Conjugate (SDC) Targeting TNFα and JAK Enzymes with a Neutrophil Elastase-Cleavable Linker for Inflammation-Site Specific Payload Release,” showcases the innovative design, preclinical proof of concept in development of ELN28 for targeted treatment of inflammatory diseases.
